I am John Snow Professor of Epidemiology at Queen Mary University of London. My current interests are in cancer epidemiology and clinical trials, with special interest in prevention and screening.
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol (2015) 16(1):67-75. PMID: 25497694
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet (2014) 383(9922):1041-8. PMID: 24333009
Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Onc (2011) 12(3):245-255. PMID: 21310658
A breast cancer prediction model incorporating familial and personal risk factors. Statist Med (2004) 23: 1111-1130. PMID: 15057881
Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet (2003) 362: 1871-1876. PMID: 14667741
I am currently Chairman of the International Breast Cancer Intervention Study (IBIS) Steering Group and the ATAC trial. I have worked extensively in breast cancer and was the first to report the effect of tamoxifen on contralateral tumours as an indicator of its potential chemopreventive role. I demonstrated that a change in mammographic breast density on endocrine treatment is a biomarker for its effectiveness.
I am involved in studies on the use of HPV assays for cervical screening, the use of flexible sigmoidoscopy for colorectal cancer screening and markers for the behaviour of early prostate cancer.
I am the statistician for several major breast cancer trials and maintain an active interest in developing new statistical methodology, especially in the area of adjustments for non-compliance and cross-over, and multi-arm clinical trials.
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials Bradley R, Braybrooke J, Gray R et al. The Lancet Oncology (2022) 23(7) 382-392
Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy Pece S, Sestak I, Montani F et al. European Journal of Cancer (2022) 164(7) 52-61
Clinical performance of methylation as a biomarker for cervical carcinoma in situ and cancer diagnosis: A worldwide study Banila C, Lorincz AT, Scibior-Bentkowska D et al. International Journal of Cancer (2022) 150(7) 290-302
Assessment of Risk Factors and Early Presentations of Parkinson Disease in Primary Care in a Diverse UK Population Simonet C, Bestwick J, Jitlal M et al. JAMA Neurology (2022) (7)
The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge Coles CE, Anderson BO, Cameron D et al. The Lancet (2022) (7)
The importance of ethnicity: Are breast cancer polygenic risk scores ready for women who are not of White European origin? Evans DG, van Veen EM, Byers H et al. International Journal of Cancer (2022) 150(7) 73-79
Burden of Mycoplasma genitalium and Bacterial Coinfections in a Population-Based Sample in New Mexico Hammer A, Gravitt PE, Adcock R et al. Sexually transmitted diseases (2021) 48(1) e186-e189
Clinical follow-up practices after cervical cancer screening by co-testing: A population-based study of adherence to U.S. guideline recommendations Perkins RB, Adcock R, Benard V et al. Preventive Medicine (2021) 153(7)
Improving estimation of Parkinson’s disease risk—the enhanced PREDICT-PD algorithm Bestwick JP, Auger SD, Simonet C et al. npj Parkinson's Disease (2021) 7(1)
Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review Atakpa EC, Thorat MA, Cuzick J et al. Cochrane Database of Systematic Reviews 2021(1)
For additional publications, please click hereI received my BSc in Mathematics and Physics from Harvey Mudd College, Claremont, California. I then studied an MSc in Mathematics at the University of London. I obtained my PhD in Mathematics from Claremont Graduate School, Claremont, California.
I was appointed John Snow Professor of Epidemiology at Queen Mary University of London. In 2017, I was awarded a CRUK Lifetime Achievement Award and a CBE.